aTyr Pharma Stock Forecast, Price & News

-0.02 (-0.42 %)
(As of 06/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume188,450 shs
Average Volume1.00 million shs
Market Capitalization$75.99 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive LIFE News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.

aTyr Pharma logo

About aTyr Pharma

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product ATYR1923 is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.66 out of 5 stars

Medical Sector

357th out of 2,100 stocks

Biological Products, Except Diagnostic Industry

50th out of 198 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions

Is aTyr Pharma a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" aTyr Pharma stock.
View analyst ratings for aTyr Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than aTyr Pharma?

Wall Street analysts have given aTyr Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but aTyr Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is aTyr Pharma's next earnings date?

aTyr Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for aTyr Pharma

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) issued its earnings results on Thursday, May, 13th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.34) by $0.17. aTyr Pharma had a negative net margin of 155.18% and a negative trailing twelve-month return on equity of 67.48%.
View aTyr Pharma's earnings history

How has aTyr Pharma's stock price been impacted by COVID-19 (Coronavirus)?

aTyr Pharma's stock was trading at $3.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LIFE shares have increased by 56.1% and is now trading at $4.73.
View which stocks have been most impacted by COVID-19

When did aTyr Pharma's stock split? How did aTyr Pharma's stock split work?

aTyr Pharma's stock reverse split before market open on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of aTyr Pharma stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for LIFE?

5 brokerages have issued 12 month target prices for aTyr Pharma's shares. Their forecasts range from $13.00 to $20.00. On average, they anticipate aTyr Pharma's stock price to reach $16.00 in the next year. This suggests a possible upside of 238.3% from the stock's current price.
View analysts' price targets for aTyr Pharma
or view top-rated stocks among Wall Street analysts.

Who are aTyr Pharma's key executives?

aTyr Pharma's management team includes the following people:
  • Dr. Sanjay S. Shukla, Pres, CEO & Director (Age 49, Pay $702.05k)
  • Ms. Jill M. Broadfoot, Chief Financial Officer (Age 59, Pay $516.11k)
  • Ms. Nancy E. Denyes Krueger, Gen. Counsel & Corp. Sec. (Age 53, Pay $477.14k)
  • Xiang-Lei Yang Ph.D., Founder
  • Ms. Ashlee Dunston, Director of Investor Relations & Corp. Communications
  • Mr. Peter Villiger, VP of Corp. Devel.
  • Dr. Ying J. Buechler, Exec. Director of Biologics Devel. & Manufacturing
  • Dr. Melissa A. Ashlock, Sr. Advisor (Age 63)
  • Dr. David J. King, Scientific Consultant (Age 62)

What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO?

3 employees have rated aTyr Pharma CEO Sanjay Shukla, M.D, M.S on Sanjay Shukla, M.D, M.S has an approval rating of 100% among aTyr Pharma's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of aTyr Pharma's key competitors?

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

Who are aTyr Pharma's major shareholders?

aTyr Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Alyeska Investment Group L.P. (6.14%), Ikarian Capital LLC (1.87%), BlackRock Inc. (1.58%), Renaissance Technologies LLC (1.51%), Acadian Asset Management LLC (0.64%) and Dimensional Fund Advisors LP (0.40%). Company insiders that own aTyr Pharma stock include Jill Marie Broadfoot, John K Clarke, Paul Schimmel and Sanjay Shukla.
View institutional ownership trends for aTyr Pharma

Which major investors are selling aTyr Pharma stock?

LIFE stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, and Renaissance Technologies LLC. Company insiders that have sold aTyr Pharma company stock in the last year include Jill Marie Broadfoot, John K Clarke, and Sanjay Shukla.
View insider buying and selling activity for aTyr Pharma
or view top insider-selling stocks.

Which major investors are buying aTyr Pharma stock?

LIFE stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Alyeska Investment Group L.P., Dimensional Fund Advisors LP, Acadian Asset Management LLC, Citadel Advisors LLC, Citadel Advisors LLC, and Geode Capital Management LLC. Company insiders that have bought aTyr Pharma stock in the last two years include Jill Marie Broadfoot, Paul Schimmel, and Sanjay Shukla.
View insider buying and selling activity for aTyr Pharma
or or view top insider-buying stocks.

How do I buy shares of aTyr Pharma?

Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is aTyr Pharma's stock price today?

One share of LIFE stock can currently be purchased for approximately $4.73.

How much money does aTyr Pharma make?

aTyr Pharma has a market capitalization of $75.99 million and generates $10.45 million in revenue each year. The biotechnology company earns $-16,220,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis.

How many employees does aTyr Pharma have?

aTyr Pharma employs 40 workers across the globe.

What is aTyr Pharma's official website?

The official website for aTyr Pharma is

Where are aTyr Pharma's headquarters?

aTyr Pharma is headquartered at 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121.

How can I contact aTyr Pharma?

aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 731-8389 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.